The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | PROMise trial update: OPN-2853 plus rux in advanced MF with inadequate response to rux alone
Adam Mead, MA, BM, BCh, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, presents the interim analysis of the PROMise study (ISRCTN12451433), a clinical trial investigating the combination of the BET inhibitor OPN-2853 with ruxolitinib (rux) in patients with advanced myelofibrosis who have had an inadequate response to rux alone. Dr Mead highlights that preliminary efficacy data show encouraging spleen response rates and symptom improvement. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
